The estimated Net Worth of Joerg Neermann is at least 152 千$ dollars as of 13 December 2022. Joerg Neermann owns over 82,000 units of Immunic stock worth over 152,000$ and over the last 5 years Joerg sold IMUX stock worth over 0$.
Joerg has made over 2 trades of the Immunic stock since 2022, according to the Form 4 filled with the SEC. Most recently Joerg bought 82,000 units of IMUX stock worth 102,500$ on 13 December 2022.
The largest trade Joerg's ever made was buying 82,000 units of Immunic stock on 13 December 2022 worth over 102,500$. On average, Joerg trades about 11,111 units every 2 days since 2019. As of 13 December 2022 Joerg still owns at least 100,000 units of Immunic stock.
You can see the complete history of Joerg Neermann stock trades at the bottom of the page.
Joerg's mailing address filed with the SEC is 1200 AVENUE OF THE AMERICAS, SUITE 200, , NEW YORK, NY, 10036.
Over the last 5 years, insiders at Immunic have traded over 174,861$ worth of Immunic stock and bought 176,506 units worth 558,583$ . The most active insiders traders include Barclay A Phillips、Joerg Neermann、Duane Nash. On average, Immunic executives and independent directors trade stock every 74 days with the average trade being worth of 15,244$. The most recent stock trade was executed by Daniel Vitt on 26 February 2024, trading 14,000 units of IMUX stock currently worth 18,340$.
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
Immunic executives and other stock owners filed with the SEC include: